Table 3 Percentage of SDV done for differing classifications of data
From: Monitoring in practice – How are UK academic clinical trials monitored? A survey
%SDV | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
100 | 60 | 50 | 30 | 20 | 15 | 10 | 5 | 0 | ||
All data | 0 | 0 | 2 | 1 | 3 | 1 | 5 | 1 | 2 | 15 |
Consent | 19 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 22 |
Eligibility criteria | 13 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 19 |
Primary endpoint reports | 13 | 0 | 0 | 1 | 0 | 0 | 3 | 1 | 0 | 18 |
Secondary endpoint reports | 4 | 1 | 1 | 1 | 1 | 0 | 6 | 1 | 2 | 17 |
SAE: Serious adverse event reports | 14 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 19 |
AE: Non-serious adverse event reports | 4 | 0 | 0 | 1 | 1 | 0 | 7 | 1 | 3 | 17 |
Selected priority data | 8 | 0 | 0 | 1 | 0 | 0 | 3 | 1 | 5 | 18 |